Long‐term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface‐antigen negative liver transplant recipients from hepatitis B core‐antibody‐positive donors

Abstract

Long-term lamivudine monotherapy was effective in preventing development of HBV infection in HBsAg-negative liver transplant recipients from HBcAb-positive donors.